Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Mann Kind's assets by the company in 2014
Mann Kind Corporation acquired by Mann Kind Corporation in 2001 |
| gptkbp:business_model |
focuses on specialty pharmaceuticals
|
| gptkbp:ceo |
gptkb:Michael_Castagna
|
| gptkbp:clinical_trial |
ongoing clinical trials for new products
Afrezza clinical trials conducts clinical research for diabetes therapies publishes clinical data in peer-reviewed journals has multiple ongoing clinical trials for new therapies |
| gptkbp:collaborations |
collaborates with various research institutions
|
| gptkbp:committee |
maintains a scientific advisory board for guidance
|
| gptkbp:community_engagement |
engages in community outreach programs
|
| gptkbp:economic_impact |
pursues market expansion opportunities.
|
| gptkbp:employees |
approximately 100
|
| gptkbp:financial_performance |
publishes quarterly financial reports
monitors financial performance closely |
| gptkbp:focus |
diabetes treatment
|
| gptkbp:founded |
gptkb:2001
|
| gptkbp:founder |
gptkb:Alfred_E._Mann
gptkb:Alfred_Mann |
| gptkbp:global_presence |
has a global presence in the pharmaceutical market
|
| gptkbp:grants |
receives research grants for diabetes studies
|
| gptkbp:headquarters |
gptkb:Valencia,_California
|
| gptkbp:healthcare |
Afrezza in 2014
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mann Kind Corporation
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:innovation |
focuses on product innovation in diabetes care
|
| gptkbp:invention |
multiple patents for inhaled drug delivery systems
|
| gptkbp:investment |
institutional investors
maintains investor relations program conducts investor presentations regularly focuses on diabetes and metabolic disorders significant investments in R& D |
| gptkbp:key_people |
gptkb:Alfred_Mann
gptkb:Harlan_W._Waksal gptkb:Michael_Castagna |
| gptkbp:language_of_instruction |
has a diverse product pipeline
|
| gptkbp:leadership |
led by experienced pharmaceutical executives
|
| gptkbp:market |
Afrezza launched in 2015
conducts market research for product positioning |
| gptkbp:market_cap |
$300 million (2021)
|
| gptkbp:marketing_strategy |
develops innovative market strategies
|
| gptkbp:partnership |
gptkb:Sanofi
gptkb:United_Therapeutics_Corporation |
| gptkbp:partnerships |
forms partnerships with healthcare providers
develops strategic partnerships for growth |
| gptkbp:products |
gptkb:Afrezza
invests in product development initiatives |
| gptkbp:regulatory_compliance |
ensures regulatory compliance for all products
received regulatory approval for Afrezza |
| gptkbp:research_focus |
inhaled insulin
|
| gptkbp:revenue |
$10 million (2020)
$10.5 million (2020) |
| gptkbp:scholarships |
offers patient support programs for Afrezza users
|
| gptkbp:social_responsibility |
committed to corporate social responsibility initiatives
|
| gptkbp:supply_chain |
manages a complex supply chain for products
|
| gptkbp:symbol |
gptkb:MNKD
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:treatment |
focuses on improving clinical outcomes for patients
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:website |
www.mannkindcorp.com
|
| gptkbp:bfsParent |
gptkb:Alfred_E._Mann
|
| gptkbp:bfsLayer |
4
|